Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.65 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
| ▸ | DAO | P14920 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 4/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20529212 | 0.84 | CYP1A2 (0.57) | B3GNT2GRIN1GRIN2BDAOMAOB | |
| SCHEMBL20529142 | 0.81 | PGR (0.45) | B3GNT2DAOMAOBKMT2AMEN1 | |
| SCHEMBL20529396 | 0.79 | PGR (0.56) | B3GNT2MAOBPGR | |
| SCHEMBL20529102 | 0.77 | MAOB (0.53) | B3GNT2DAOMAOBPGRLMNA | |
| SCHEMBL30279787 | 0.77 | MAOB (0.53) | B3GNT2DAOMAOBPGRLMNA | |
| SCHEMBL20529240 | 0.77 | MAOB (0.44) | B3GNT2GRIN1GRIN2BDAOMAOB | |
| SCHEMBL20529151 | 0.77 | B3GNT2 (0.61) | B3GNT2GRIN1GRIN2BDAOMAOB | |
| SCHEMBL20529030 | 0.76 | B3GNT2 (0.74) | B3GNT2GRIN1GRIN2BKMT2AMEN1 | |
| SCHEMBL2267066 | 0.75 | CYP1A2 (0.67) | B3GNT2DAOKMT2AMEN1CYP1A2 | |
| SCHEMBL8348807 | 0.72 | DAO (0.59) | B3GNT2GRIN1GRIN2BDAOKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | disclosed |
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | INVENTIVA (FR) | 2020-04-16 | — | — | US | disclosed |
| EP-3606921-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | Inventiva (FR) | 2020-02-12 | — | — | EP | disclosed |
| CN-110709396-A | Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma | 伊文蒂瓦公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2018185266-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | YAP1, TEAD2, TEAD1 | B3GNT2 4826/4885GRIN1 4448/4885GRIN2B 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.